Dr. Hamza Coban, MD

Dr. Coban practices at Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut.

Dr. Coban's NPI, 1922539121, was assigned on March 21, 2017. Dr. Coban holds Connecticut license 069523.

Dr. Coban's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD, at 263 Farmington Ave, Farmington, CT 06030.

Dr. Coban's primary practice is Uconn Health Carole and Ray Neag Comprehensive Cancer Center - HOPD in Farmington, Connecticut. Dr. Coban is also affiliated with UConn John Dempsey Hospital. The medical group on file is UConn Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Coban practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Coban's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Coban is licensed in Connecticut.

CMS data shows 140 Medicare services from Dr. Coban across 4 procedure codes in 2024, for 97 Medicare patients. Medicare paid $8,689 for them. Every service was in an office.

CMS counts 97 Medicare patients who saw Dr. Coban in 2024. The largest group is under 65, with 41 patients. 57% of them have high blood pressure, and 54% have high cholesterol. 51% are also on Medicaid. Their average risk score is 1.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Coban's median patient age at 54, with 70% women.

In 2024, Dr. Coban wrote 778 Medicare Part D claims for 113 patients. 87% of them were for generic drugs. CMS names the drug for 552 of them, across 24 drugs with 11 or more claims each, at $167,735 in total drug cost. In 2023, CMS named 110 claims across 5 drugs.

Dr. Coban accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Coban, published from 2017 to 2023. 2021 was the busiest year, with 3. The most frequent topics are Multiple Sclerosis and Antibodies, Monoclonal, Humanized. Dr. Coban has published most often in Mult Scler Relat Disord. Dr. Coban's most frequent co-authors are Joseph Rossi Berger, MD, Ann C. Collier and Nicholas Scott Haberli, MD.

CMS Open Payments shows 14 general payments to Dr. Coban from 5 drug and device companies from 2022 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. EMD Serono, Inc. paid the most, $9,906.